- Complications
- Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus
-
Yongin Cho, Hye-Sun Park, Byung Wook Huh, Yong-ho Lee, Seong Ha Seo, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, So Hun Kim
-
Diabetes Metab J. 2023;47(2):232-241. Published online January 19, 2023
-
DOI: https://doi.org/10.4093/dmj.2021.0355
-
-
7,177
View
-
271
Download
-
11
Web of Science
-
14
Crossref
-
 Abstract
 PDF Supplementary Material PubReader  ePub
- Background
We aimed to evaluate whether non-alcoholic fatty liver disease (NAFLD) with or without sarcopenia is associated with progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM).
Methods
We investigated 852 T2DM patients who underwent abdominal ultrasonography, bioelectrical impedance analysis, and carotid artery ultrasonography at baseline and repeated carotid ultrasonography after 6 to 8 years. NAFLD was confirmed by abdominal ultrasonography, and sarcopenia was defined as a sex-specific skeletal muscle mass index (SMI) value <2 standard deviations below the mean for healthy young adults. SMI was calculated by dividing the sum of appendicular skeletal mass by body weight. We investigated the association between NAFLD with or without sarcopenia and the progression of carotid atherosclerosis.
Results
Of the 852 patients, 333 (39.1%) were classified as NAFLD without sarcopenia, 66 (7.7%) were classified as sarcopenia without NAFLD, and 123 (14.4%) had NAFLD with sarcopenia at baseline. After 6 to 8 years, patients with both NAFLD and sarcopenia had a higher risk of atherosclerosis progression (adjusted odds ratio, 2.20; P<0.009) than controls without NAFLD and sarcopenia. When a subgroup analysis was performed on only patients with NAFLD, female sex, absence of central obesity, and non-obesity were significant factors related to increased risk of plaque progression risk in sarcopenic patients.
Conclusion
NAFLD with sarcopenia was significantly associated with the progression of carotid atherosclerosis in T2DM patients.
-
Citations
Citations to this article as recorded by  - Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy decreases lean body mass and appendicular skeletal muscle mass index even until one year after the final treatment in patients with B-cell non-Hodgkin lymphoma
Sanshiro Nakao, Daiji Ngayama, Chiaki Nakaseko, Naomi Shimizu
Journal of Chemotherapy.2025; 37(4): 365. CrossRef - Relationship between Muscle Mass by Bioimpedance and Vascular Complications in Type 2 Diabetes Mellitus
Alejandra Calderón, Cristina Arteaga, Elizabeth Quiroga, Lisbeth Reales, Marcelo Pilamunga, Fernanda Marizande, Alberto Bustillos
Salud, Ciencia y Tecnología.2025;[Epub] CrossRef - Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study
Yebei Liang, Xiaoqi Ye, Min Pan, Yijun Chen, Yeqing Yuan, Li Luo
BMC Gastroenterology.2025;[Epub] CrossRef - Sarcopenia and non-alcoholic fatty liver disease - complex pathogenetic relationships
V. A. Akhmedov, V. S. Marinenko
Experimental and Clinical Gastroenterology.2025; (9): 110. CrossRef - Impact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease
Eugene Han, Sin Yung Woo, Justin Y. Jeon, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee, Yong-ho Lee
Diabetes Research and Clinical Practice.2025; 224: 112209. CrossRef - Association of lean metabolic dysfunction‐associated steatotic liver disease with carotid plaque progression in patients with type 2 diabetes mellitus
Youngjoon Kim, Yongin Cho, Yong‐ho Lee, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, So Hun Kim
Journal of Diabetes Investigation.2025;[Epub] CrossRef - Association between sarcopenic obesity and cardiovascular diseases: the role of systemic inflammation indices
Yuhong Luo, Chen Xin, Yuhua Liu, Yan Xu, Guixin Liu, Binru Han
Frontiers in Medicine.2025;[Epub] CrossRef - Metabolic-associated fatty liver disease and sarcopenia: A double whammy
Aditya Viswanath, Sherouk Fouda, Cornelius James Fernandez, Joseph M Pappachan
World Journal of Hepatology.2024; 16(2): 152. CrossRef - Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease
Suprabhat Giri, Prajna Anirvan, Sumaswi Angadi, Ankita Singh, Anurag Lavekar
World Journal of Gastrointestinal Pathophysiology.2024;[Epub] CrossRef - Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis
Chao Deng, Qifeng Ou, Xuee Ou, Ding Pan
BMJ Open.2024; 14(5): e078933. CrossRef - Clinical Characteristics of Sarcopenia in Nonalcoholic Fatty Liver Disease: A Systemic Scoping Review
Tingdan Ye, Ke Mi, Lin Zhu, Jonathan Li, Calvin Q. Pan
Obesity Facts.2024; : 1. CrossRef - Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?
Catherine Stankevicius, Rachel H. Davis, Dep Huynh, Martine Hatzi, Stephanie Morgillo, Alice S. Day
Journal of Digestive Diseases.2024; 25(11-12): 645. CrossRef - Association of nonalcoholic fatty liver disease and carotid media‐intima thickness: A systematic review and a meta‐analysis
Manouchehr Khoshbaten, Sepideh H. Maleki, Sara Hadad, Amrit Baral, Ana V. Rocha, Laxmi Poudel, Alireza Abdshah
Health Science Reports.2023;[Epub] CrossRef - Cardiometabolic risk factors in patients with type 2 diabetes and sarcopenia
Yu. G. Samoilova, M. V. Matveeva, E. A. Khoroshunova, D. V. Podchinenova, L. L. Maksimova, G. G. Gorbach, A. B. Trivozhenko, V. A. Avkhimenko
Cardiovascular Therapy and Prevention.2023; 23(1): 3655. CrossRef
|
KDA
